The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research
Renaming Palliative Cancer Therapies: Call It What It Is
Oncologist. 2024 Mar 18:oyae039. doi: 10.1093/oncolo/oyae039. Online ahead of print.NO ABSTRACTPMID:38498046 | DOI:10.1093/oncolo/oyae039 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Kimberly E Kopecky Toby C Campbell Source Type: research
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Source Type: research
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research
Renaming Palliative Cancer Therapies: Call It What It Is
Oncologist. 2024 Mar 18:oyae039. doi: 10.1093/oncolo/oyae039. Online ahead of print.NO ABSTRACTPMID:38498046 | DOI:10.1093/oncolo/oyae039 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Kimberly E Kopecky Toby C Campbell Source Type: research
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Source Type: research
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research
Renaming Palliative Cancer Therapies: Call It What It Is
Oncologist. 2024 Mar 18:oyae039. doi: 10.1093/oncolo/oyae039. Online ahead of print.NO ABSTRACTPMID:38498046 | DOI:10.1093/oncolo/oyae039 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Kimberly E Kopecky Toby C Campbell Source Type: research
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Statewide Cancer Drug Repository Reducing Waste in the Setting of Shortage Crisis
This article introduces pilot outcomes for a solution to improve access to medications while also decreasing medication waste. Cancer drug repositories are an innovative patient-centered model where donations of unused cancer medications from patients are repurposed and provided to patients who are most vulnerable and disproportionately harmed by financial toxicity. This model demonstrates efficiency and sustainability that complements integrated care and provides an approach to increase medication access and decrease medication waste.PMID:38484400 | DOI:10.1093/oncolo/oyae040 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Emily R Mackler Siobhan Norman Farah Jalloul Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Statewide Cancer Drug Repository Reducing Waste in the Setting of Shortage Crisis
This article introduces pilot outcomes for a solution to improve access to medications while also decreasing medication waste. Cancer drug repositories are an innovative patient-centered model where donations of unused cancer medications from patients are repurposed and provided to patients who are most vulnerable and disproportionately harmed by financial toxicity. This model demonstrates efficiency and sustainability that complements integrated care and provides an approach to increase medication access and decrease medication waste.PMID:38484400 | DOI:10.1093/oncolo/oyae040 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Emily R Mackler Siobhan Norman Farah Jalloul Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Statewide Cancer Drug Repository Reducing Waste in the Setting of Shortage Crisis
This article introduces pilot outcomes for a solution to improve access to medications while also decreasing medication waste. Cancer drug repositories are an innovative patient-centered model where donations of unused cancer medications from patients are repurposed and provided to patients who are most vulnerable and disproportionately harmed by financial toxicity. This model demonstrates efficiency and sustainability that complements integrated care and provides an approach to increase medication access and decrease medication waste.PMID:38484400 | DOI:10.1093/oncolo/oyae040 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Emily R Mackler Siobhan Norman Farah Jalloul Source Type: research
